Navigation Links
Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962)
Date:11/6/2009

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- America's Specialty Medicines Companies (ASMC), an informal working group of mid-market and smaller innovator pharmaceutical companies, today expressed concerns about H.R. 3962, the "Affordable Health Care for America Act," introduced by House Democrats last Thursday. These smaller companies fear that the cumulative effect of a host of provisions in H.R. 3962 will hinder their efforts to bring new medicines to market.

From required rebates to mandated discounts to new regulations, H.R. 3962 repeatedly raises new barriers for small companies seeking to fund life-saving research. Unlike larger companies, smaller companies typically must use cash generated from the sale of their own products for research. Unfortunately, the bill starves them of those necessary revenues. Its new burdens will damage the viability of small companies, and ultimately, put at risk the health of future patients who need medicines that smaller companies are more likely to develop.

Smaller companies generate much of the innovation in the pharmaceutical industry. Their work ranges over the entire spectrum from drugs for some of the most common diseases like cancer and diabetes to those for smaller, underserved populations with rare diseases. Without smaller companies' investment in the research and development of breakthrough products, many patients would go without any effective treatment. In many cases, these very treatments contain costs by eliminating the need for more expensive care.

"Small pharmaceutical companies often bring needed specialty medications to market when no one else will. Unfortunately, H.R. 3962 would stifle that innovation and prevent those efforts. Ultimately, the patients who need these medicines will suffer most," said Steve Cannon, an attorney representing ASMC.

But the damage runs deeper. H.R. 3962 will cut off small drug companies' ability to bring drugs developed overseas to the U.S. market as well. Small companies frequently license U.S. rights to those drugs, conduct U.S. clinical trials on them, and seek U.S. approval of them. Much of that economic activity would stop under H.R. 3962 - hurting the U.S. economy, killing U.S. jobs, and depriving U.S. patients of needed drugs.

Despite our concerns, ASMC looks forward to continuing to work with Congress to produce health care legislation that will produce better care and better drugs for all Americans.

SOURCE America's Specialty Medicines Companies


'/>"/>
SOURCE America's Specialty Medicines Companies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... Oct. 4, 2017  According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):